Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial). (20th August 2018) - Popat, Rakesh; Brown, Sarah R.; Flanagan, Louise; Hall, Andrew; Gregory, Walter; Kishore, Bhuvan; Streetly, Matthew; Oakervee, Heather; Yong, Kwee; Cook, Gordon; Low, Eric; Cavenagh, Jamie; et al.